

Since more than 15 years, we have provided custom assay development, compound profiling, high-throughput screening services and collaborations in over 200 drug discovery projects. We can help with any service in your workflow to move your discovery forward from target identification through safety and toxicity testing. The Innopharma Screening Platform has a state-of-theart equipment for carrying out assay development projects and screening campaigns with different technological approaches.

TECHNOLOGICAL APPROACHES:

SPA); Radioactivity (Filtration and Absorbance: Fluorescence intensity and polarization; Luminescence; FRET and Homogeneous Time-Resolved Fluorescence; BRET; Alphascreen: Fluorescence Lifetime Imaging; Automated patch-clamp; Label free (Dynamic Mass Redistribution); Automated mobility shift (Lab on a chip); High Content Screening and UPLC/MS/MS.

We collaborate with Medicina Xenómica group, which shares with us their genomics technology platforms.

PHARMACOGENOMICS STUDIES

Discovery and analysis of genomic biomarkers for:



Patient and disease stratification



Response to drugs (efficacy and toxicity)

Identification of novel therapeutic targets:



Genome wide and candidate gene association studies (e.g. Illumina, Affymetrix, Sequenom, Agilent)



Next Generation Sequencing (e.g. lon Torrent, Ion Proton, SOLiD) - specific application to pharmacogenomic panels and exome sequencing

Innopharma Platform Capabilities

Target Lead optimization identification

Target validation

CTP and road map

Assay development Candidate cascade set up

Hit finding

Hit to Lead Lead optimization

Preclinical development

Clinical trials


Genomics: Target ID, genomic biomarkers, patient stratification

DNA/RNA extraction

Blood/cell/tumor/microbiome sample

DNA/RNA analysis

Genome/transcriptome (genotyping, sequencing, gene expression)



In vitro pharmacology: Hit finding, hit to lead, lead optimization

Drug discovery program design

CTP definition/ feasibility/druggability/screening cascade design

Chemical compound libraries

Chemical library available including proprietary compounds selected in silico based on biological and structural diversity

Customized services

Ad hoc assay development and screening

Assay development

Target based/phenotypic (recombinant or in human samples)

Preliminary ADME/Tox

Microsomal and plasma stability, plasma protein binding, Caco2, cytochrome inhibition, hERG, genotoxicity

De-risking programs

Internal drug discovery programs up to proof of concept stage

Screening

High capacity screening platform of the ERIC EU-OPENSCREEN (<u>www.euopenscreen.eu</u>) covering different targets (receptors, transporters, enzymes, nuclear receptors, ion channels, protein-protein interactions) and technologies



TARGET-BASED ASSAYS

GPCRs

Radioligand binding assays: ADO, NA, DA, 5-HT, M, H₁, LTB₄...

GPCRs

Second messenger assays: ADO, NA, DA, 5-HT...

GPCRs

Beta-arrestin translocation assays-BRET: GPR35; mu opioid; CX₃CR1...

Nuclear receptors

E.g. AR, ER, PPAR and prostanoids receptors

Enzymes

Kinases (250 functional assays), phosphodiesterases (15 activity assays); BACE-1 (beta-secretase), acetylcholinesterase; MAO-A, MAO-B; epigenetic enzymes

lon channels Voltage-gated channels: Ca²⁺, K*, hERG, Na*... Membrane ligand-gated channels: NMDA; 5-HT₃; GABAA...

Transporters

DAT, NAT, 5-HTT ...

CELL-BASED ASSAYS

> Phenotypic assays (e.g. cell viability, signaling pathway assays, disease-related assays)

Target deconvolution strategies

> Biomolecular imaging (FRET microscopy, High-content analysis)

ADMET

P450 profiling - induction and inhibition.

Targets engagement, permeability (Caco-2); P-glycoprotein substrate; aqueous solubility (pH-dependent).

PRELIMINARY ADMET AND SAFETY ASSAYS

Safety

Specialized cellular assays: cell viability and cell toxicity.

In vitro safety panel, including functional pharmacological profiling.

CUSTOMIZED ASSAYS

We work to understand your goals and tailor a solution to fit your project guidelines. Our dedicated scientific professionals have access to and expertise in assay solutions across multiple target classes and detection platforms.

We are committed to deliver high-quality data and comprehensive reporting on time, with dedicated project management and proactive communication throughout the project.

We also provide support at every stage of discovery—from instrument setup to screening, profiling, and custom services through data analysis. Our team of specialists is comprised of experienced scientists that can help you find answers efficiently and accurately.

The Innopharma platform provides scientific-technical services for drug discovery:

Pharmacogenomics studies to identify biomarkers and novel therapeutic targets

Assays development, set up miniaturization and automation

Identification of hits, leads and candidates. In vitro preliminary ADMET and safety

SERVICES

Customized assays development, target engagement, phenotypic and deconvolution assays

Chemical libraries (drugs for repurposing focused libraries, compounds selected in silico over more than 500 clinically relevant targets, epigenetic-targeted compounds)

Assessment and execution of complete screening cascades for R&D



BioFarma is an early drug discovery research linked the group Innopharma Screening Platform at the University of Santiago Compostela. It has expertise and offers collaboration with public and private institutions in drug discovery projects. BioFarma has a large experience in assaying small molecules and in the fine-tuning and automatization of techniques for implementation in HTS.

Find out more at: http://www.usc.es/biofarma/

CIMUS Research Center Avenida de Barcelona S/N Campus Vida, E - 15782 Santiago de Compostela Telephone: (+34) 881 815 459 biofarma.group@usc.es





